

ARC101 in Advanced Solid Tumors

NCT06672185

Status	RECRUITING
Phase	Phase 1
Sponsor	Third Arc Bio
Enrollment	70 participants

Key Eligibility Criteria

Inclusion (4)

- Locally advanced or metastatic solid tumor ovarian, testicular or other Claudin 6+ cancers
- Measurable or evaluable disease, per RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate organ function

Exclusion (7)

- Active CNS involvement
- Malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study drug.
- Presence of uncontrolled ascites
- Toxicity related to prior anticancer therapy that has not returned to Grade d1 or baseline levels
- Clinically significant pulmonary compromise
- ... and 2 more (see full listing online)

Locations (12 total)

Massachusetts General Hospital, Boston, Massachusetts, United States
START Midwest, Grand Rapids, Michigan, United States
START San Antonio, LLC., San Antonio, Texas, United States
... and 9 more locations